Founded in 2014, Damae Medical’s mission is to let dermatologists observe skin at the cellular scale directly during consultations. Its core product, deepLive™, delivers instant, non-invasive cellular imaging supported by a real-time, CE-certified AI engine. Backed by more than a decade of R&D and over 250 scientific publications, deepLive™ is already installed in 120+ sites across 15+ countries, spanning hospitals and private practices. The system is used from initial diagnosis to intra-operative surgical guidance, helping thousands of patients avoid unnecessary biopsies, repeat surgeries and long waiting times. With the technology now commercially launched, the company plans to broaden access beyond early pioneer centers and make digital biopsy a routine part of dermatological care. The newly secured Series B funding strengthens its financial position and fuels this expansion. Damae Medical continues to focus on accelerating adoption, improving accuracy and reducing invasiveness in skin-cancer management.

Total raised

$25M

Funding rounds

3

Latest round

Series B

Latest activity

Nov 2025